CD274 and hepatocellular carcinoma: The combination of the programmed death ligand 1 (PD-L1) inhibitor, atezolizumab, and the anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, has shown promising results for unresectable HCC [3,4].